Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNA
Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top scientists believe they are just starting to scratch the full potential of its gene-silencing siRNA ...
Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top scientists believe they are just starting to scratch the full potential of its gene-silencing siRNA ...
